



# aap Implantate

## **Progression of LOQTEQ portfolio**

Q316 results highlighted a challenging quarter despite being broadly in line with company guidance (sales of €2.9m and an EBITDA loss of €1.8m). However, US sales were above company expectations (Q3: €0.7m, 9M: €2.0m) and are indicative that the initiatives put in place to drive sales in more established markets are beginning to prove fruitful. aap Implantate will need a solid Q4 to deliver on its FY16 revenue guidance, which it now expects to be at the lower end (€13.0-15.0m).

#### Q316 results

aap Implantate reported sales and EBITDA in line with its guidance. It reported sales of €2.9m (guidance €2.5-4.0m) and an EBITDA loss of €1.8m (guidance loss of €1.2-2.0m). EBITDA was burdened by one-time effects due to a customer receivables value adjustment (€0.2m) and termination of a licence agreement with the co-developer of the LOQTEQ technology (€0.3m, providing sustainable relief to earnings in the long term). This resulted in a recurring EBITDA loss of €1.3m. Importantly, initiatives to drive sales in established markets are beginning to demonstrate traction, with US sales higher than management expectations and customer access in the DACH region being extended. Progress remains tempered by the missing contribution to sales in China. Continued improvement in the US remains key to the growth trajectory and to the success of the LOQTEQ portfolio.

### Key areas of technology progression

LOQTEQ, aap's proprietary anatomically shaped trauma plates, continues to grow its indication coverage, recently adding periprosthetic and polyaxial ankle systems. This is important as indication expansion will enable the company to build scale that can enable bundling offers, which in turn would enable surgeons to be consistent in their treatment approach and therefore drive more conversions to the technology. aap is also actively engaged with both the European and US regulatory authorities to gain CE marking and FDA approval respectively for its antibacterial silver coating technology. aap indicates that it expects progression in 2017.


# Valuation: A year of change, with upside possible

Q3 results demonstrate that aap is executing on its strategy of becoming a traumafocused company. M&A continues to be significant in this sector and we expect a
gradual shift away from scale-based acquisitions towards transactions that
enhance value through innovation and enable a focus on category leadership and
portfolio depth. As the company continues to drive sales of LOQTEQ in western
Europe and the US, alongside the stabilisation of sales in BRICS and SMIT
countries and the implementation of cost reduction measures, we could see a
return to sustained growth, which could attract M&A value.

Historical financials						
Year end	Revenue (€m)	PBT (€m)	EPS (c)	DPS (c)	P/E (x)	Yield (%)
12/14	30.6	(1.7)	0.0	0.0	N/A	N/A
12/15	28.0	(5.3)	(0.2)	0.0	N/A	N/A
Source: aap Implantate accounts						

Healthcare equipment & services





# Share details Code AAQ Listing XETRA Shares in issue 30.8m

#### **Business description**

aap Implantate is a German medtech company, focused on developing, manufacturing and selling products for bone fractures. This is primarily the LOQTEQ trauma plating system alongside earlier-stage innovations including antibacterial silver coating technology and magnesium-based implants.

#### Bull

- Proven technology and strong IP protection.
- Transition to a pure trauma player enables a focus on building the core business.
- Focused on driving sales in more established markets – increased distributors in the US and an experienced head of US sales engaged.

#### Bear

- FY15 sales were down by 9% on FY14. Trauma sales were down 16%. Results in 2016 are indicating an improvement, but risk remains in the execution of the strateov.
- The orthopaedic space is dominated by a few large players, making it difficult for a small player to gain traction.
- Impact of increased sales focus on established markets will not be fully demonstrated until FY16 and into 2017.

#### **Analysts**

Dr Linda Pomeroy +44 (0)20 3077 5738 Lala Gregorek +44 (0)20 3681 2527

healthcare@edisongroup.com

aap Implantate is a client of Edison Investment Research Limited



Edison, the investment intelligence firm, is the future of investor interaction with corporates. Our team of over 100 analysts and investment professionals work with leading companies, fund managers and investment banks worldwide to support their capital markets activity. We provide services to more than 400 retained corporate and investor clients from our offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority (<a href="https://www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584">www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584</a>). Edison Investment Research (NZ) Limited (Edison NZ) is the New Zealand subsidiary of Edison. Edison NZ is registered on the New Zealand Financial Services only. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is regulated by the Securities and Exchange Commission. Edison Investment Research Limited (Edison Aus) [46085869] is the Australian subsidiary of Edison and is not regulated by the Australian Securities and Investment Commission. Edison Germany is a branch entity of Edison Investment Research Limited (4794244). <a href="https://www.edisongroup.com">www.edisongroup.com</a>

#### DISCLAIMER

DISCLAMENT Copyright 2016 Edison Investment Research Limited. All rights reserved. This report has been commissioned by applimplantate and prepared and issued by Edison for publication globally. All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report. Opinions contained in this report represent those of the research department of Edison at the time of publication. The securities described in the Investment Research may not be eligible for sale in all jurisdictions or to certain categories of investment assert in six securities and Exchange Commission. Edison US relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information and orresponding state securities laws. As such, Edison does not offer or provide personalised advice. We publish information provided by us should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed in any manner whatsoever as, personalised advice. Also, our website and the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers (for use in their roles as financial advisers or brokers (for use in their office as a financial advisers or brokers (for use in their office as a financial advisers or brokers (for use in their office as a financial advisers or brokers (for use in their office as a financial advisers or brokers (for use in their office as a fina